Conventional Bilateral rTMS vs. Bilateral Theta Burst Stimulation for Late-Life Depression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

163 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-31

Study Completion Date

2020-04-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial will compare conventional sequential bilateral rTMS to a bilateral theta burst stimulation protocol. The right and left dorsolateral prefrontal cortices will be the site of stimulation in both treatment conditions. The site of stimulation will be targeted using MRI co-registration. The study seeks to determine if the bilateral theta burst protocol has similar effectiveness to the conventional bilateral rTMS protocol in treating major depression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Randomized Controlled Trial of Conventional vs Theta Burst rTMS

NCT01887782

Major Depressive Disorder

COMPLETED NA

Left vs. Right Non-Inferiority Trial

NCT04999553

Depression Major Depressive Disorder Major Depressive Episode

RECRUITING NA

Efficacy of Intermittent ThetaBurst Stimulation Compared to 10 Hz Stimulation on Dorsolateral Prefrontal Cortex in Treatment Resistant Major Depressive Disorder: a Double-blind Randomized Study

NCT02376491

DEPRESSION

COMPLETED NA

Comparing Uni- and Bi-lateral TBS in Major Depression

NCT04142996

Major Depressive Episode

RECRUITING NA

Comparing Different Patterns of rTMS in Major Depression

NCT02778035

Depression; Bipolar Disorder

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Convential Sequential Bilateral rTMS

LFR followed by HFL.

1 Hz stimulation of the right DLPFC for 600 pulses followed by 10 Hz stimulation of the left DLPFC for 3000 pulses (4 seconds on 26 seconds off for 75 trains). Treatment will occur 5 times per week for 4 to 6 weeks.

Group Type ACTIVE_COMPARATOR

LFR followed by HFL

Intervention Type DEVICE

Magventure Cool B70 Coil with RX100 Stimulator

Bilateral Theta Burst Stimulation

cTBS followed by iTBS.

continuous theta burst stimulation (cTBS) of the right DLPFC for 600 pulses followed by intermittent theta burst stimulation (iTBS) of the left DLPFC for 600 pulses. Treatment will occur 5 times per week for 4 to 6 weeks.

Group Type EXPERIMENTAL

cTBS followed by iTBS

Intervention Type DEVICE

Magventure Cool B70 Coil with RX100 Stimulator

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LFR followed by HFL

Magventure Cool B70 Coil with RX100 Stimulator

Intervention Type DEVICE

cTBS followed by iTBS

Magventure Cool B70 Coil with RX100 Stimulator

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* are an outpatient
* are ≥60 years old
* have a Mini-International Neuropsychiatric Interview (MINI 6.0)67 confirmed diagnosis of MDD, with a current MDE
* have failed to achieve a clinical response to an adequate dose of an antidepressant based on an Antidepressant Treatment History Form (ATHF) score of \> 3 in the current episode or have failed to tolerate two separate trials of an antidepressant
* have a score \> 17 on the MADRS
* have had no increase or initiation of any psychotropic medication in the 4 weeks prior to screening
* have normal electrolytes, hemoglobin and thyroid functioning based on pre-study blood work
* Pass the TMS adult safety screening (TASS) questionnaire
* Are able to have an MRI

Exclusion Criteria

* have a history of substance dependence or abuse within the last 3 months
* have a concomitant major unstable medical illness determined by one of the study physicians
* have active suicidal intent
* have a lifetime MINI diagnosis of bipolar I or II disorder, or primary psychotic disorder
* have current psychotic symptoms
* have a diagnosis of obsessive compulsive disorder, post-traumatic stress disorder (current or within the last year), anxiety disorder (generalized anxiety disorder, social anxiety disorder, panic disorder), or dysthymia, assessed by a study investigator to be primary. One of these comorbidities will not be exclusionary if they are not deemed to be primary.
* have a diagnosis of any personality disorder, and assessed by a study investigator to be primary and causing greater impairment than MDD
* have presumed or probable dementia or clinical evidence of dementia as assessed by a Short Blessed Test score of greater than 10.
* did not respond to a course of ECT in the current depressive episode
* have received rTMS in the current episode, patients who have had rTMS in a previous episode would be eligible
* have a history of a primary seizure disorder or a seizure associated with an intracranial lesion.
* have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed
* have a implanted electronic device that is currently function such as a defibrillator
* currently take more than lorazepam 2 mg daily (or equivalent) or any dose of an anticonvulsant
* if participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study
* non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview).

Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No